search
Back to results

Study of Abnormal Blood Clotting in Children With Stroke

Primary Purpose

Abnormalities, Blood Coagulation Disorder, Brain Disease

Status
Completed
Phase
Locations
United States
Study Type
Observational
Intervention
Sponsored by
National Institute of Neurological Disorders and Stroke (NINDS)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an observational trial for Abnormalities focused on measuring Factor V Leiden, Prothrombin Mutation, Antiphospholipids, Cerebral Infarction, Thrombophilia, Porencephaly, Perinatal Stroke, Healthy Mothers, Healthy Children

Eligibility Criteria

undefined - 45 Years (Child, Adult)All SexesDoes not accept healthy volunteers

INCLUSION CRITERIA: CHILDREN WITH A HISTORY OF PORENCEPHALY OR STROKE: Children less than 18 years of age with a history of porencephaly or cerebral infarction (stroke). Children less than 18 years of age with a history of spastic hemiplegic or quadriplegic cerebral palsy (ICD-9 codes 343.1, 343.2, 343.3, 343.4, 343.8 and 343.9) with radiographic evidence of porencephaly or stroke. A diagnosis of porencephaly as defined by a fluid-filled cavity within the cerebral hemispheres which may or may not communicate with CSF spaces and confirmed by at least one imaging method including computed tomography (CT), magnetic resonance (MR) and or Doppler ultrasonography. A diagnosis of cerebral infarction (stroke) as defined by a new focal neurologic deficit lasting greater than or equal to 24 hours and presumably due to a vascular process (ICD-9 codes 430-437) and confirmed by brain imaging, either computed tomography (CT), magnetic resonance (MR) or Doppler ultrasonography. Informed consent of the parent. Informed assent of the child, when available. FIRST-DEGREE RELATIVES OF CHILDREN WITH PORENCEPHALY OR STROKE: Full biological first-degree relatives of children with a history of porencephaly or stroke enrolled in this study. Informed consent of each participant. Informed assent of each participant under 18 years, when available. HEALTHY CHILDREN: Children less than 18 years of age. Informed consent of the parent. Informed assent of the child when available. HEALTHY MOTHERS: Women between 18 and 45 years of age. History of full-term pregnancy. Informed consent of the participant. EXCLUSION CRITERIA: CHILDREN WITH A HISTORY OF PORENCEPHALY OR STROKE: Children greater than 18 years of age. Maternal history of cocaine abuse during pregnancy. History of cancer. History of other chromosomal or metabolic disorder. History of trauma and or child abuse. Isolated subdural hematomas. History of aneurysm or vascular malformations. Congenital heart disease. Sickle cell disease. History of CNS infection. HEALTHY CHILDREN: Children greater than 18 years of age. Maternal history of cocaine abuse during pregnancy. History of cancer. History of other chromosomal or metabolic disorder. History of trauma and or child abuse. Isolated subdural hematomas. History of aneurysm or vascular malformations. Congenital heart disease. Sickle cell disease. History of CNS infection. History of stroke or porencephaly. HEALTHY MOTHERS: Volunteer has biological children without a history of cancer, head trauma, aneurysm, chromosomal or metabolic disorder, congenital heart disease, sickle cell disease, meningitis or encephalitis, or stroke. Cocaine use during pregnancy.

Sites / Locations

  • National Institutes of Health Clinical Center, 9000 Rockville Pike

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
November 3, 1999
Last Updated
June 30, 2017
Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
search

1. Study Identification

Unique Protocol Identification Number
NCT00001927
Brief Title
Study of Abnormal Blood Clotting in Children With Stroke
Official Title
Study of Abnormal Acquired and Genetic Coagulation Factors in Children With Porencephaly and Stroke
Study Type
Observational

2. Study Status

Record Verification Date
May 4, 2011
Overall Recruitment Status
Completed
Study Start Date
February 22, 1999 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
May 4, 2011 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)

4. Oversight

5. Study Description

Brief Summary
Effective treatment and prevention strategies for childhood stroke and porencephaly can only be developed once the causes are understood. There is increasing evidence that inherited and acquired coagulation abnormalities alone or in combination with environmental factors, predispose to arterial and venous thrombosis. Inherited abnormalities of factor V Leiden, prothrombin, protein C, protein S, and antithrombin III may account for many of these thromboses. At present there is little information on the existing distribution of these coagulation anomalies in children with thrombosis. Recent reports also suggest that these clotting abnormalities may be responsible for some instances of intracranial hemorrhage, porencephaly, cerebral palsy and fetal death. This study will measure the frequency of several coagulation factor abnormalities (factor V Leiden, prothrombin 20210A, protein C, protein S, antithrombin III, and antiphospholipid antibodies) in children with a history of porencephaly and stroke, and will compare these to the prevalence of these mutations in population controls and family members. We will also describe the exogenous conditions which in concert with these coagulation factors, may have led to the development of thrombosis in these children....
Detailed Description
OBJECTIVES: Effective treatment and prevention strategies for childhood stroke and porencephaly can only be developed once the causes are understood. There is increasing evidence that inherited and acquired coagulation abnormalities, alone or in combination with environmental factors, predispose to arterial and venous thrombosis. Inherited abnormalities of factor V leiden, prothrombin, protein C, protein S, and antithrombin III may account for many of these thromboses. At present there is little information on the existing distribution of these coagulation anomalies in children with thrombosis. Recent reports suggest that these clotting abnormalities may be responsible for some instances of intracranial hemorrhage, porencephaly, cerebral palsy and fetal death. The objectives of this protocol are: 1) to determine the frequency of coagulation abnormalities in children with porencephaly or stroke as compared to healthy children, 2) to determine the frequency of coagulation abnormalities in children with porencephaly or stroke as compared to their family members, 3) to determine the frequency of coagulation abnormalities in mothers of children with stroke as compared to mothers of healthy children, and 4) to describe the exogenous conditions, which in concert with coagulation factors, may have led to the development of thrombosis in children with stroke. STUDY POPULATION: This study will examine: 1) children with a history of porencephaly or stroke, 2) their biological mothers, fathers, and siblings, 3) healthy volunteer children, and 4) healthy volunteer mothers. DESIGN: This is a case-control study conducted at the National Institute of Neurological Disorders and Stroke. Children with a history of porencephaly or stroke before 18 years of life, their first-degree relatives, healthy volunteer children, and healthy volunteer mothers will be enrolled. Each subject may complete a blood draw, buccal smear, questionnaire, and/or review of medical records depending on their study group. OUTCOME MEASURES: This study will measure the frequency of several coagulation factors among the study's different population groups as well as examine the exogenous conditions that may have contributed to stroke in these children. Analysis will be descriptive and quantitative.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Abnormalities, Blood Coagulation Disorder, Brain Disease, Cerebrovascular Accident, Vascular Disease
Keywords
Factor V Leiden, Prothrombin Mutation, Antiphospholipids, Cerebral Infarction, Thrombophilia, Porencephaly, Perinatal Stroke, Healthy Mothers, Healthy Children

7. Study Design

Enrollment
130 (Actual)

10. Eligibility

Sex
All
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
INCLUSION CRITERIA: CHILDREN WITH A HISTORY OF PORENCEPHALY OR STROKE: Children less than 18 years of age with a history of porencephaly or cerebral infarction (stroke). Children less than 18 years of age with a history of spastic hemiplegic or quadriplegic cerebral palsy (ICD-9 codes 343.1, 343.2, 343.3, 343.4, 343.8 and 343.9) with radiographic evidence of porencephaly or stroke. A diagnosis of porencephaly as defined by a fluid-filled cavity within the cerebral hemispheres which may or may not communicate with CSF spaces and confirmed by at least one imaging method including computed tomography (CT), magnetic resonance (MR) and or Doppler ultrasonography. A diagnosis of cerebral infarction (stroke) as defined by a new focal neurologic deficit lasting greater than or equal to 24 hours and presumably due to a vascular process (ICD-9 codes 430-437) and confirmed by brain imaging, either computed tomography (CT), magnetic resonance (MR) or Doppler ultrasonography. Informed consent of the parent. Informed assent of the child, when available. FIRST-DEGREE RELATIVES OF CHILDREN WITH PORENCEPHALY OR STROKE: Full biological first-degree relatives of children with a history of porencephaly or stroke enrolled in this study. Informed consent of each participant. Informed assent of each participant under 18 years, when available. HEALTHY CHILDREN: Children less than 18 years of age. Informed consent of the parent. Informed assent of the child when available. HEALTHY MOTHERS: Women between 18 and 45 years of age. History of full-term pregnancy. Informed consent of the participant. EXCLUSION CRITERIA: CHILDREN WITH A HISTORY OF PORENCEPHALY OR STROKE: Children greater than 18 years of age. Maternal history of cocaine abuse during pregnancy. History of cancer. History of other chromosomal or metabolic disorder. History of trauma and or child abuse. Isolated subdural hematomas. History of aneurysm or vascular malformations. Congenital heart disease. Sickle cell disease. History of CNS infection. HEALTHY CHILDREN: Children greater than 18 years of age. Maternal history of cocaine abuse during pregnancy. History of cancer. History of other chromosomal or metabolic disorder. History of trauma and or child abuse. Isolated subdural hematomas. History of aneurysm or vascular malformations. Congenital heart disease. Sickle cell disease. History of CNS infection. History of stroke or porencephaly. HEALTHY MOTHERS: Volunteer has biological children without a history of cancer, head trauma, aneurysm, chromosomal or metabolic disorder, congenital heart disease, sickle cell disease, meningitis or encephalitis, or stroke. Cocaine use during pregnancy.
Facility Information:
Facility Name
National Institutes of Health Clinical Center, 9000 Rockville Pike
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20892
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
6895379
Citation
Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest. 1981 Nov;68(5):1370-3. doi: 10.1172/jci110385.
Results Reference
background
PubMed Identifier
8093743
Citation
Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briet E. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet. 1993 Jan 16;341(8838):134-8. doi: 10.1016/0140-6736(93)90003-y.
Results Reference
background
PubMed Identifier
8916933
Citation
Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996 Nov 15;88(10):3698-703.
Results Reference
background

Learn more about this trial

Study of Abnormal Blood Clotting in Children With Stroke

We'll reach out to this number within 24 hrs